

Evaluation of Serum Concentration of Copeptin, Resistin, Irisin and Some Immunological Variables in Polycystic Ovary Syndrome Infected Patients in Kirkuk City

Nagham Imad Abdul Hameed

Department of–Biology, Education Directorate Open Educational College of Science,
 Ministry of Education- Kirkuk, Iraq

Zina Abdulmunem Abdulrazaaq Al-doory

Department of Biology, College of Education for Women, University of Kirkuk, Kirkuk, Iraq

Received: 2024, 15, Sep

Accepted: 2024, 21, Sep

Published: 2024, 29, Oct

Copyright © 2024 by author(s) and Scientific Research Publishing Inc. This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).



Open Access

<http://creativecommons.org/licenses/by/4.0/>

Annotation: Background: Polycystic ovary syndrome is most common disorder in the endocrine system in women of fertile and reproductive age, as it is associated with irregular menstruation, indicators of insulin resistance, and androgen excess. . **Objective:** The current study was designed to evaluation of Polycystic ovary syndrome-PCOS infection effects on some variables such as Copeptin, Resistin and Irisin, Luteinizing hormone-LH, Follicle stimulating hormone-FSH, Testosterone . **Methods:** The study was conducted on 50 patients infected with PCOS and 30 healthy women (uninfected), who attended the Al-Jumhuri general hospital of Kirkuk city from 15/5/2024-15/6/2024. The results : results showed a significant ($P<0.05$) increase in serum level of (Copeptin, Resistin and Irisin, LH, T.T) and a significant decrease in level of (FSH) in PCOS infected patients compared healthy women . **Conclusion:** Copeptin, Resistin, Irisin and some variables are important physiological and immunological

biomarkers that can support the diagnosis of PCOS.

Keywords: polycystic ovary syndrome, Copeptin, Resistin, Irisin, Tumor necrosis factor.

Introduction

Polycystic ovary syndrome is a heterogeneous syndrome that affects women of reproductive age, with risks for heart and metabolic diseases. Obesity and insulin resistance are the most common, about 50-70%, respectively, and they are two important features of polycystic ovary syndrome, but they are not considered diagnostic criteria. Androgen excess and obesity are Insulin resistance is associated with the risk of low-grade chronic inflammation, metabolic risk, and heart disease in obese women with the syndrome, so recent research is focusing on the gradual discovery of biomarkers in metabolic changes with polycystic ovary syndrome (vonica *et al.*, 2020). Polycystic ovary syndrome is widespread worldwide and poses a threat to women's health in general, as symptoms of excessive hair growth, infertility, and menstrual disorders appear, as well as metabolic problems, insulin resistance, and type 2 diabetes. The causes of the disease are still not completely clear, as there is a role for environmental and genetic factors such as glandular disorders (Hong *et al.*, 2020).

Polycystic ovary syndrome develops in women by stimulating the ovaries by increasing the production of the male hormone (testosterone), either by excessive secretion of luteinizing hormone from the anterior pituitary gland and a high level of insulin in the blood due to the improvement of the ovaries for this stimulation, or it may be a decrease in the level of sex hormones associated with globulin, which leads to To increase androgen (STRAUUS., 2003).

Copeptin is a 39-amino acid glycopeptide, which consists of a signal peptide, arginine (Jochberger *et al.*, 2006). Polycystic Ovarian Syndrome, a common endocrine illness, affects approximately 5 to 10% of women of reproductive age. Copeptin has significant associations with cardiometabolic parameters regardless of age or weight. (Jyotsna., 2024).

Resistin is a small protein rich in cysteine, which is secreted by mature white adipocytes. It is secreted in the form of a polypeptide and was first named by Steppan. Its levels increase in types of obesity caused by diet and genetics and decrease with the use of anti-diabetic drugs. However, it is mainly secreted by Mononuclear cells in peripheral blood (Chen., 2013 and Zou., 2005), as their levels have been associated with a high incidence of cardiovascular disease and deaths (Wang., 2020). Many studies have indicated a relationship between the hormone resistin and polycystic ovary syndrome. Studies have found that the hormone is elevated (. Hall., 2019 and Mancinelli ., 2009) or is within its normal levels (Kumar., 2011). Some studies have noted that resistin and insulin resistance are a positive relationship (Mohiyiddeen., 2010 and . Baskind., 2016), but they failed. Other studies prove this (Stamatiades., 2018 and Cahoreau., 2015).

Irisin is a hormone composed of 112 amino acids. It was discovered for the first time in 2012 by researcher Bostrom and his group and was named after the Greek goddess of the messenger, Iris (Boström., 2012). It is an adipomycin substance that is secreted mainly from skeletal muscle and adipose tissue. Small amounts of it are also produced from the testicles and liver. The pancreas, brain, and spleen (Martinez ., 2018).

Tumor necrosis factor - $\text{TNF } \alpha$ is one of the inflammatory cytokines that is responsible for determining the nature of the immune response (Liberale., 2021). Tumor necrosis factor is a

multifunctional cytokine that is manufactured by adipose, endothelial, and fibroblast cells (Kien., 2015) and participates in regulating immunity, reproduction, and apoptosis (Włodarczyk et al., 2020). It plays a role in regulating the ovarian cycle, so it plays a role during the growth and development of ovarian follicles (Mahdi ., 2011).

Materials and Method

Examination of blood samples:- Serum separated from five ml of venous blood were obtained from the patients and control groups to assessed Lactoferrin, Iron, ferritin, IL-6, Zn by using the American company Monbined, by the American company . All variables were measured by ELISA.

Statistical Analysis

The process of collecting data for the samples used for the study and analyzing them statistically was done using the (SPSS) system by extracting the arithmetic mean and standard deviation. The Test was also used to analyze differences between the main and secondary groups. Significant differences were chosen for these groups under a probability level of $P \leq 0.05$.

Results

Estimation the physiological and immunological variables in the two study groups:

Table (1) shows the mean $\pm$ S.D of physiological parameter in the two study groups.

Groups Parameter	Mean $\pm$ SD	
	Control n=30	PCOS n=50
LH (mIU/ml)	7.44 $\pm$ 1.25	15.45 $\pm$ 3.12
FSH (mIU/ml)	28.31 $\pm$ 3.56	12.49 $\pm$ 1.45
Testosterone (ng/ml)	5.14 $\pm$ 0.95	9.67 $\pm$ 1.54
Copeptin (mg/dl)	56.14 $\pm$ 13.65	85.43 $\pm$ 10.34
Resistin (ng/ml)	2.76 $\pm$ 0.42	5.22 $\pm$ 1.08
Irisin (ng/ml)	654.76 $\pm$ 20.65	865.87 $\pm$ 22.876
TNF- α (pg/ml)	55.4 $\pm$ 7.32	95.33 $\pm$ 8.35

Results of current research showed a significant elevated in (LH, Testosterone, Copeptin, Resistin, Irisin, TNF- α) and a significant decrease in the (FSH) in the serum of patients compared healthy women). at its level, the probability of $P \leq 0.05$. as in the following figures:




Figure (1): LH concentration in the blood serum of all groups

Figure (2): FSH concentration in the blood serum of all groups




Figure (3): Testosterone concentration in the blood serum of all groups




Figure (4): Resistin concentration in the blood serum of all groups

Figure (5): Copeptin concentration in the blood serum of all groups




Figure (6): Irisin concentration in the blood serum of all groups

Figure (7): TNF-α concentration in the blood serum of all groups

Discussion

The results of current study are consistent with results of some studies (Hussain., 2021) (Jadav., 2020) from the message, which indicated in their study an increase in level of luteinizing hormone in blood serum of patients with polycystic ovary syndrome compared to healthy women, as it reinforces the reason for the resulting increase. It may also occur as a result of psychological stress

or an imbalance in the diet (Henríquez., 2020). An increase in the level of luteinizing hormone causes a defect in the ovulation process or the absence of ovulation in the follicular cycle, Although luteinizing hormone initiates ovulation and then stimulates the corpus luteum to create steroid hormones, a high quantity of it lowers the efficiency of aromatase and hinders the development of the oocyte. (Al-Jubouri, 2014). While Hus., 2020, indicated that the diagnosis of polycystic ovary syndrome is made with the best sensitivity and specificity with an LH/FSH ratio greater than 1 (Hasan *et al.*, 2020).

On the other hand, the results of the current research indicated a decrease in concentration of follicle-stimulating hormone in blood serum of patients with PCOS compared healthy women . The slight decrease in the hormone level may be because a high prolactin concentration may inhibit FSH secretion (Eldar-Geva., 2001). also (Melmed., 2004) indicated that the decrease in the hormone level may be due to the production of adrenaline from the adrenal gland, which in turn affects the concentration of FSH from During androgen secretion.

The results of the research also indicated an elevated in testosterone in women infected with PCOS, as the results agreed with some studies (Sahlah and Aseel.,2019) indicated elevated of testosterone level, Excessive androgens are one of the most important causes of polycystic ovary syndrome. Androgens are secreted as a result of abnormal dysfunction in the ovary, and poor follicle formation is the primary effect of excess androgens that disrupt normal androgen synthesis. (Shabbir., 2023).

Also the results of this study showed an increase in levels of resistin in blood serum of women with PCOS. the results agreed with some studies (İlyas., 2009 and ahreh., 2021) who indicated a significant elevated in resistin hormone in women infected with PCOS, and on other hand, a study showed that the concentration of resistin are higher in overweight and obese females than in thin women, regardless of the occurrence of Polycystic ovary syndrome (ABBAS.,2021 and Hussein., *et al.*,2024), as resistin is secreted by blood cells and adipose tissue, which inhibits glucose tolerance and insulin sensitivity. Fat cells are the most important cause of insulin resistance because they reduce the number of insulin receptors, and since they secrete the hormone resistin, insulin resistance occurs, so weight loss It helps reduce insulin resistance and improve blood sugar measurement.

On the other hand, the research results indicated an increase in copeptin levels, as the result agreed with some studies (adel.,2020 and Mutaz., 2018 and Hani.,2022), which indicated an increase in copeptin levels in patients PCOS. also they studied 150 women with polycystic ovary syndrome. Copeptin levels are associated with insulin resistance, but because of low sensitivity, it cannot be considered a sign of insulin resistance. (Widecka., 2019). a study also found that there is a relationship between copeptin levels, insulin resistance, and metabolic syndrome ((Saleem., 2009). Therefore, it was found that high levels of copeptin in the blood may be an important diagnostic indicator in patients suffering from polycystic ovary syndrome. (Gruden *et al*, 2014).

Also the Serum irisin concentration were significantly rise in PCOS women compared with healthy women this result agree with (Zhang., 2018 and M.S. BOSTANCI., 2015). also we found that metformin therapy leads to lower irisin levels in women with polycystic ovary syndrome (Telagareddy., 2024). irisin could be considered as a biomarker for prognosis and therapy followup in patients with PCOS (Saba.,2023). In the current study, it was found that there was an increase in irisin levels, and this is consistent with the results (Park *et al* ., 2013), the elevated concentration of serum irisin were determined in patients with metabolic syndrome. however, it has also been suggested that the elevated irisin level may represent a state of irisin resistance(GARCÉS., 2014) .

Similar investigations have suggested that circulating irisin levels were greater in patients with PCOS than in normal healthy controls, but this link disappeared when the researchers compared them to healthy controls with the same BMI as patients with PCOS. (Mancuso., 2019 and. Kukla.,2020), Furthermore, it has been proposed that BMI, a weight status indicator, may operate as a modulator of circulating irisin alterations in PCOS patients. Furthermore, this meta-analysis found that circulating irisin was lowered in response to hyperinsulinemia in patients with PCOS,

but to a higher amount than in healthy controls, implying that people with PCOS function in this regard may be affected. (Chen.,2022).

The research results are consistent with the results of (Shorakae., 2018 and Al-Musawy., 2018), who indicated an increase in level of tumor necrosis factor in women with polycystic ovary syndrome, as the reason is attributed to inflammatory factors, as PCOS is characterized by the presence of low-grade chronic inflammation (Dadachanji.,2018 and Wedad and Mohanad.,2021) and that an increase in tumor necrosis factor in women with polycystic ovary syndrome is an indication of Immune dysfunction in affected women, as hyperandrogenism, which is a hallmark of this condition, can affect common forms in the genes that encode tumor necrosis factor and its type 2 receptors (Al-Musawy., 2018).by increasing receptors Androgen receptor mRNA- in women with polycystic ovary syndrome that stimulate glucose uptake in the fasting state by monocytes mononuclear cells, which activates the nuclear transcription factor in those cells, causing increased production of inflammatory cytokines, including tumor necrosis factor (Lainez., 2019).

References

1. ABBAS, H. S. (2021). The Clinical Cruciality of Resistin in the Emanation of Polycystic Ovary Syndrome in Female Individuals and Its Prediction. *International Journal of Pharmaceutical Research*, 13(1).
2. adel Elboghdady aly mohamed salah elfeshawy, abeer abd elfatah, Ahmed MOHAMMED Saeed . opeptin and Obestatin Levels in Polycystic Ovary women and their Relation to Obesity, insulin metabolism and Cardiovascular diseases.Al-Azhar international medical journal. olume 1, Issue 4 - Serial Number 14, 2020: 44-49.
3. ahereh Raeisi, Hossein Rezaie, Mina Darand, Akram Taheri, Nazila Garousi, Bahman Razi, Leonardo Roever, Circulating resistin and follistatin levels in obese and non-obese women with polycystic ovary syndrome: A systematic review and meta-analysis. *PLoS One*. 2021; 16(3): e0246200.
4. Al-Musawy, S.H.; Al-Saimary, I.E.; Flaifil, M.S. (2018). Levels of cytokines profile in polycystic ovary syndrome. *Med J Babylon* .15:124-8.
5. Baskind, N. E., & Balen, A. H. (2016). Hypothalamic–pituitary, ovarian and adrenal contributions to polycystic ovary syndrome. *Best Practice & Research Clinical Obstetrics & Gynaecology*, 37, 80-97. 140. Stamatiades GA, Kaiser UB. Gonadotropin regulation by pulsatile GnRH: signaling and gene expression. *Mol cell endocrinol*. 2018 Mar 5;463:131-41.
6. *Biochem. Cell. Arch.* Vol. 18, No. 2, pp. 2427-2430, 2018.
7. Boström, P., Wu, J., Jedrychowski, M. P., Korde, A., Ye, L., Lo, J .C, Long, J. Z. A PGC1- α -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature*, 2012; 481(7382), 463-468 .
8. Cahoreau, C., Klett, D., & Combarnous, Y. (2015). Structure– function relationships of glycoprotein hormones and their subunits' ancestors. *Frontiers in endocrinology*, 6, 26.
9. Chen PP, Jia R, Liu YP, Cao MY, Zhou L, Zhao ZM. Progress of Adipokines in Female Reproductive System: A focus on Polycystic Ovary Syndrome. *Front Endocrinol*. 2022;936.
10. Chen, X., Jia, X., Qiao, J., Guan, Y., & Kang, J. (2013). Adipokines in reproductive function: a link between obesity and polycystic ovary syndrome. *J Mol Endocrinol*, 50(2), R21-37.
11. Dadachanji, R.; Shaikh, N. and Mukherjee, S. (2018). Genetic variants associated with hyperandrogenemia in PCOS pathophysiology. *Genetics research international*, Volume 2018, Article ID 7624932, 12 pages .

12. Eldar-Geva, T.; Spitz, I. M.; Groome, N. P.; Margalioth, E. J. and Homburg, R. Follistatin and activin A serum concentrations in obese and non-obese patients with polycystic ovary syndrome. *Human reproduction*.2001; 16(12): 2552-56.
13. GARCÉS MF, PERALTA JJ, RUIZ-LINARES CE, LOZANO AR, POVEDA NE, TORRES-SIERRA AL, ESLAVA-SCHMALBACH JH, ALZATE JP, SÁNCHEZ AY, SANCHEZ E, ANGEL-MÜLLER E, RUÍZ-PARRA AI, DIÉGUEZ C, NOGUEIRAS R, CAMINOS JE. Irisin levels during pregnancy and changes associated with the development of preeclampsia. *J Clin Endocrinol Metab* 2014; 99: 2113-2119.
14. Gruden G, Landi A and Bruno G (2014) Natriuretic peptides, heart, and adipose tissue new findings and future developments for diabetes research. *Diabetes Care* 37, 2899–2908.
15. Hall, J.E. (2019), *Neuroendocrine control of the menstrual cycle*, in Yen and Jaffe's reproductive endocrinology. Elsevier. p. 149-166. e5.
16. Hani M. Abdelsalam¹, Ahmed Abdul HamedHendawy¹, Mohamed Hussein Ibrahim², Noha Ahmed Ibrahim¹, Sherein F. El-sayed². Linkage Between Copeptin and Polycystic Ovary Syndrome. *NeuroQuantology*|August 2022|Volume20|Issue10|Page 6988-6995|doi:10.14704/nq.2022.20.10.NQ55691.
17. Hasan, H. A., Selman, M. O., & Jawad, A. (2020). Polycystic Ovary Syndrome: does it Increase the Level of Cancer Antigen125? *Merit Research Journal of Medicine and Medical Sciences*, 8(7), 327–332.
18. Hong, X., Qin, P., Huang, K., Ding, X., Ma, J., Xuan, Y., Zhu, X., Peng, D., & Wang, B. (2020). Association between polycystic ovary syndrome and the vaginal microbiome: A casecontrol study. *Clinical Endocrinology*, 93(1), 52–60.
19. Hussein, Riam Ali. Evaluation of some hormones and biochemical variables in the blood of women with polycystic ovary syndrome in the city of Baghdad. Master Thesis. Tikrit University. College of Science. chemistry department. 2021.
20. Hussein Mohammed Abdullah, Shatha Hizem Shaker and Hana Attiya Salman. 2024. Study the concentrations of Leptin, adiponectin and some parameters in women with polycystic ovaries syndrome. *GSC Biological and Pharmaceutical Sciences*, 28(02), 116–121.
21. İlyas Çapoğlu¹, Fuat Erdem, Abdullah Uyanık, Hamdullah Turhan . Serum levels of resistin and hsCRP in women with PCOS . *Cent. Eur. J. Med.* • 4(4) • 2009 • 428-432.
22. Jadav, P. M. (2020). A study of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH) in women of Polycystic Ovarian Disease (PCOD) at Tertiary Care Hospital of Gujarat, India. *International Journal of Clinical Biochemistry and Research*, 5(1), 112–115. <https://doi.org/10.18231/2394-6377.2018.0022>
23. Jochberger S, Morgenthaler N G, Mayr V D, Luckner G, Wenzel V and Ulmer H (2006) Copeptin and arginine vasopressin concentrations in critically ill patients. *J Clin Endocrinol Metab.* 91, 4381–4386.
24. Jyotsna Mirabel Coelho¹, Prema D'Cunha², AR Shivashankara³ . Serum Copeptin as a Biomarker of Polycystic Ovarian Syndrome and its Correlation with Metabolic Syndrome Components: A Cross-sectional Analytical Study. *Journal of Clinical and Diagnostic Research*. 2024 Jul, Vol-18(7): QC01-QC04.
25. K. A. Walters, R. B. Gilchrist, W. L. Ledger, H. J. Teede, D. J. Handelsman, and R. E. Campbell, “New Perspectives on the Pathogenesis of PCOS: Neuroendocrine Origins,” *Trends Endocrinol. Metab.*, vol. 29, no. 12, pp. 841–852, 2018, doi: 10.1016/j.tem.2018.08.005.
26. Kien, C. L.; Bunn, J. Y.; Fukagawa, N. K.; and Poynter, M. E. (2015). Lipidomic evidence that lowering the typical dietary palmitate to oleate ratio in humans decreases the leukocyte

- production of proinflammatory cytokines and muscle expression of redox-sensitive genes. *J of nutritional biochemistry*, 26(12), 1599–1606.
27. Kukla M, Skladany L, Menżyk T, Derra A, Stygar D, Skonieczna M, et al. Irisin in liver cirrhosis. *J Clin Med*. 2020;9(10):3158.
 28. Kumar, P., & Sait, S. F. (2011). Luteinizing hormone and its dilemma in ovulation induction. *Journal of human reproductive sciences*, 4(1), 2.
 29. Lainez, N. M. and Coss, D. (2019). Obesity, neuroinflammation, and reproductive function. *Endocrinology*, 160(11), 2719-2736.
 30. Liberale, L.; Ministrini, S.; Carbone, F.; Camici, G. G. and Montecucco, F. (2021). Cytokines as therapeutic targets for cardio-and cerebrovascular diseases. *Basic Research in Cardiology*, 116(1), 1-26
 31. M.S. BOSTANCI 1, N. AKDEMIR1, B. CINEMRE2, A.S. CEVRIOGLU1, S. ÖZDEN1, O. ÜNAL1. Serum irisin levels in patients with polycystic ovary syndrome. *European Review for Medical and Pharmacological Sciences*. 2015; 19: 4462-4468.
 32. Mahdi B.M. (2011). Role of some cytokines on reproduction, *Middle East Fertility Society Journal*, Volume 16, Issue 3, Pages 220-223.
 33. Mancinelli, R., Onori, P., Gaudio, E., DeMorrow, S., Franchitto, A., Francis, H., & Alpini, G. (2009). Follicle-stimulating hormone increases cholangiocyte proliferation by an autocrine mechanism via cAMP-dependent phosphorylation of ERK1/2 and Elk-1. *American Journal of Physiology-Gastrointestinal and Liver Physiology*, 297(1), G11-G26.
 34. Mancuso P, Bouchard B. The impact of aging on adipose function and adipokine synthesis. *Front Endocrinol*. 2019;10:137.
 35. Martinez Munoz, I. Y., Camarillo Romero, E. d. S., & Garduno Garcia, J. d. J. Irisin a novel metabolic biomarker: present knowledge and future directions. *International journal of endocrinology*, 2018 .
 36. Melmed, S. and Jameson, L. In *Harrison principles of internal medicine*. New York Mc Graw Hill Professional. 2004.
 37. Mohiyiddeen, L., & Nardo, L. G. (2010). Single-nucleotide polymorphisms in the FSH receptor gene and ovarian performance: future role in IVF. *Human Fertility*, 13(2), 72-78.
 38. Entedhar R. Sarhat, Madlen Qassm Abba. Estimation the activity of Copeptin, insulin, and C-peptide from patients with polycystic ovary syndrome. *Tikrit Journal of Pure Science* 23 (4) 2018.
 39. PARK KH, ZAICHENKO L, BRINKOETTER M, THAKKAR B, SAHIN-EFE A, JOUNG KE, TSOUKAS MA, GELADARI EV, HUH JY, DINCER F, DAVIS CR, CROWELL JA, MANTZOROS CS. Circulating irisin in relation to insulin resistance and the metabolic syndrome. *J Clin Endocrinol Metab* 2013; 98: 4899-4907.
 40. Saba Khair Alddin Ibrahim. Assessment of Serum Irisin and Vaspin in Women with Polycystic Ovary Syndrome in Mosul City. *Pharmacogn J*. 2023; 15(1): 212-215
 41. Saleem U, Khaleghi M, Morgenthaler NG. Plasma carboxy-terminal provasopressin (copeptin): A novel marker of insulin resistance and metabolic syndrome. *J Clin Endocrinol Metab*. 2009;94(7):2558-64.
 42. Sahlah, Kh. Abbas and Aseel Sh. Abdullah. Lymphocytosis and Increases in Complement Protein C3 Level in Women with Polycystic Ovarian Syndrome. 2019 *Indian Journal of Public Health Research & Development*, October 2019, Vol.10, No. 3291-3295

43. Shabbir, S., Khurram, E., Moorthi, V.S. et al. The interplay between androgens and the immune response in polycystic ovary syndrome. *J Transl Med* 21, 259 (2023).
44. Shorakae, S.; Ranasinha, S.; Abell, S.; Lambert, G.; Lambert, E.; de Courten, B. and Teede, H. (2018). Inter-related effects of insulin resistance, hyperandrogenism, sympathetic dysfunction and chronic inflammation in PCOS. *Clinical endocrinology*, 89(5), 628-633.
45. STRAUSS III, J. F. (2003). Some new thoughts on the pathophysiology and genetics of polycystic ovary syndrome. *Annals of the New York Academy of Sciences*, 997(1), 42–48.
46. Szinnai G, Morgenthaler N G, Berneis K, Struck J, Müller B, Keller U and Christ-Crain M (2007) Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. *J Clin Endocrinol Metab.* 92, 3973–3978.
47. Telagareddy, Radhakrishna; Kumar, Padala Ravi; Pattanaik, Sudhi Ranjan; Dash, Deepak Kumar; Patro, Debasish; Sahoo, Bijay K.; Sahu, Mahija1. Serum Irisin in Polycystic Ovary Syndrome and its Alteration with Metformin Intervention. *Indian Journal of Endocrinology and Metabolism* 28(1):p 91-97, Jan–Feb 2024.
48. Vonica, C. L., Farcas, A. D., Roman, G., Muresan, A. A., Fodor, A., Cernea, S., & Georgescu, C. E. (2020). Metabolomic biomarkers of polycystic ovary syndrome related-obesity: a review of the literature. *Revista Romana de Medicina de Laborator*, 28(3), 241–255.
49. Wang, C., Huang, X., Tian, S., Huang, R., Guo, D., Lin, H., ... & Wang, S. (2020). High Plasma Resistin Levels Portend the Insulin Resistance Associated Susceptibility to Early Cognitive Decline in Patients with Type 2 Diabetes Mellitus. *Journal of Alzheimer's disease*, (Preprint), 1-9.
50. Widecka J, Osegowska K, Banasewska B, Kasienko A, Safranow K, BraneckaWosniak D, et al. Is copeptin a new potential biomarker of insulin resistance in polycystic ovary syndrome? *Ginekol Pol.* 2019;90(3):115-21. Doi: 10.5603/ GP.2019.0021.
51. Wedad Mahmood Lahmood Al-Obaidi and Mohanad Hasan Mahmood Al-Izzi. 2021. Study of Hepcidin and Many Physiological and Hematological Parameters in Women with Polycystic Ovary in Kirkuk City. *Annals of R.S.C.B.*, ISSN:1583-6258, Vol. 25, Issue 3, 2021, Pages. 7494 - 7504 .
52. Włodarczyk, M.; Ciebiera, M. and Nowicka, G. (2020). TNF- α G-308A genetic variants, serum CRP-hs concentration and DNA damage in obese women. *Mol Biol Rep* 47, 855–866 .
53. X Fang, L Li, R Liu, C Zhang, H Liu, M Tan, G Yang. association between circulating irisin levels and different phenotypes of polycystic ovary syndrome. *J Endocrinol Invest.* . 2018 Dec;41(12):1401-1407.
54. Zou, C. C., Liang, L., Hong, F., Fu, J. F., & Zhao, Z. Y. (2005). Serum adiponectin, Resistin levels and non-alcoholic fatty liver disease in obese children. *Endocrine journal*, 52(5), 519-524.